The Oxford Covid-19 vaccine shows a ‘strong immune response’ among the elderly as well as young people, scientists have said.
Data on the safety and immune responses among those taking part in phase two of the Oxford University trials has been submitted for peer review in a medical journal.
But the early findings have been discussed by Professor Andrew Pollard, director of Oxford Vaccine Group, before publication who noted the promising results across all age groups. Oxford Mail.
In a statement, Oxford University said: "These early results covering trial volunteers from the UK in the 56-69 and 70+ age groups have been submitted to a peer-review journal, and we hope to see their publication in the coming weeks.
